Identification of mutations in the PARK2 gene in Serbian patients with Parkinson's disease

M. Z. Jankovic*, V. Dobricic, N. Kresojevic, V. Markovic, I. Petrovic, M. Svetel, T. Pekmezovic, I. Novakovic, V. Kostic

*Corresponding author for this work
2 Citations (Scopus)


Mutations in the PARK2 (PRKN) gene are the most common cause of autosomal-recessive (AR) juvenile parkinsonism and young-onset Parkinson's disease (YOPD). >100 different variants have been reported, including point mutations, small indels and single or multiple exon copy number variations. Mutation screening of PARK2 was performed in 225 Serbian PD patients (143 males and 82 females) with disease onset before 50 years and/or positive family history with apparent AR inheritance. All coding regions and their flanking intronic sequences were amplified and directly sequenced. Whole exon multiplications or deletions were detected using Multiple Ligation Probe Amplification (MLPA) method. We identified 12 PD patients with PARK2 mutations (5.3%). Five patients (2.2%) had biallelic mutations and seven (3.1%) were single mutation carriers. Patients with compound heterozygous mutations had earlier onset of the disease compared to non-carriers (p = 0.005) or heterozygotes (p = 0.001). Other clinical features in mutation carriers were not different compared to non-carriers. In our cohort, sequence and dosage variants were equally represented in patients, inducing their first symptoms mainly before the age of 30. For efficient genetic testing strategy, patients with early, especially juvenile onset of PD were strong candidates for both dosage and sequence variants screening of PARK2 gene.

Original languageEnglish
JournalJournal of the Neurological Sciences
Pages (from-to)27-30
Number of pages4
Publication statusPublished - 15.10.2018


Dive into the research topics of 'Identification of mutations in the PARK2 gene in Serbian patients with Parkinson's disease'. Together they form a unique fingerprint.

Cite this